TheraRadar

Pharma Intelligence, Simplified

Data updated: Mar 10, 2026

FINACEA

AZELAIC ACID
Immunology Approved 2002-12-24
3
Indications
--
Phase 3 Trials
23
Years on Market

Details

Status
Prescription
First Approved
2002-12-24
Routes
TOPICAL
Dosage Forms
GEL, AEROSOL, FOAM

Companies

Active Ingredient: AZELAIC ACID

FINACEA Approval History

Loading approval history...

What FINACEA Treats

1 indications

FINACEA is approved for 1 conditions since its original approval in 2002. These indications span multiple therapeutic areas including oncology, immunology, and more.

  • Rosacea
Source: FDA Label
🔬

Active Pipeline

Pro

Ongoing clinical trials by development phase

Loading...

Key Completed Trials

Pro

Completed studies with published results, ranked by significance

Loading...
📊

Trial Timeline

Full development history with FDA approval milestones

Loading...
Understanding FDA Approval Types
Count Type What it means
- ORIG Original approval - drug first enters market
- SUPPL - Efficacy New indication (new disease/condition approved)
- SUPPL - Labeling Label text changes (warnings, dosing updates)
- SUPPL - Manufacturing Production changes (new facility)
- SUPPL - Chemistry Formulation changes (new dosage strength)

Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.

FINACEA FDA Label Details

Pro

Indications & Usage

FDA Label (PDF)

Azelaic acid gel, 15% is indicated for topical treatment of the inflammatory papules and pustules of mild to moderate rosacea. Limitations of Use Although some reduction of erythema which was present in patients with papules and pustules of rosacea occurred in clinical studies, efficacy for treatment of erythema in rosacea in the absence of papules and pustules has not been evaluated. Azelaic acid gel, 15% is indicated for topical treatment of the inflammatory papules and pustules of mild to moderate rosacea . Limitations of Use Efficacy for treatment of erythema in rosacea in the absence of p...

FINACEA Patents & Exclusivity

Latest Patent: Feb 2029

Patents (4 active)

US9211259 Expires Feb 28, 2029
US9265725 Expires Dec 8, 2027
US10117812 Expires Oct 18, 2027
US7700076 Expires Sep 18, 2027
Source: FDA Orange Book

Want competitive intelligence?

See who's developing similar drugs and track their progress

View Pipeline Dashboard

Data Sources

Data sourced from official FDA and NIH databases. Click links to verify on original sources.